{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:40:46Z","timestamp":1792006846396,"version":"4.4.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"DOI":"10.1007\/s00408-026-00887-x","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:06:09Z","timestamp":1777305969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating Biomarkers for Predicting Disease Progression in Idiopathic Pulmonary Fibrosis: Insights into Precision Medicine"],"prefix":"10.1007","volume":"204","author":[{"given":"Parinya","family":"Ruenwilai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattraporn","family":"Tajarernmuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriporn C.","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipon","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krekwit","family":"Shinlapawittayatorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"887_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","volume":"22","author":"TM Maher","year":"2021","unstructured":"Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM et al (2021) Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 22:197","journal-title":"Respir Res"},{"key":"887_CR2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788\u2013824","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713698","volume":"8","author":"L Ses\u00e9","year":"2021","unstructured":"Ses\u00e9 L, Nunes H, Cottin V, Israel-Biet D, Crestani B, Guillot-Dudoret S et al (2021) Gender differences in idiopathic pulmonary fibrosis: Are men and women equal? Front Med 8:713698","journal-title":"Front Med"},{"key":"887_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M et al (2017) Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 3:17074","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"887_CR5","doi-asserted-by":"publisher","first-page":"1901760","DOI":"10.1183\/13993003.01760-2019","volume":"55","author":"M Kreuter","year":"2020","unstructured":"Kreuter M, Polke M, Walsh SL, Krisam J, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T, Flaherty K (2020) Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur Respirat J 55(4):1901760","journal-title":"Eur Respirat J"},{"key":"887_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1183\/09031936.00152609","volume":"36","author":"O Nishiyama","year":"2010","unstructured":"Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K et al (2010) A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 36:1067\u20131072","journal-title":"Eur Respir J"},{"key":"887_CR7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1148\/radiol.2463062200","volume":"246","author":"AC Best","year":"2008","unstructured":"Best AC, Meng J, Lynch AM, Bozic CM, Miller D, Grunwald GK et al (2008) Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 246:935\u2013940","journal-title":"Radiology"},{"key":"887_CR8","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00074-2016","author":"Y Bauer","year":"2017","unstructured":"Bauer Y, White ES, de Bernard S, Cornelisse P, Leconte I, Morganti A et al (2017) MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res. https:\/\/doi.org\/10.1183\/23120541.00074-2016","journal-title":"ERJ Open Res"},{"key":"887_CR9","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","volume":"5","author":"TM Maher","year":"2017","unstructured":"Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA et al (2017) An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med 5:946\u2013955","journal-title":"Lancet Respir Med"},{"key":"887_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17476348.2019.1553620","volume":"13","author":"R Inchingolo","year":"2019","unstructured":"Inchingolo R, Varone F, Sgalla G, Richeldi L (2019) Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. Expert Rev Respir Med 13:39\u201351","journal-title":"Expert Rev Respir Med"},{"key":"887_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S2213-2600(18)30185-1","volume":"6","author":"M Neighbors","year":"2018","unstructured":"Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C et al (2018) Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir Med 6:615\u2013626","journal-title":"Lancet Respir Med"},{"key":"887_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S2213-2600(19)30255-3","volume":"7","author":"TM Maher","year":"2019","unstructured":"Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I et al (2019) Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med 7:771\u2013779","journal-title":"Lancet Respir Med"},{"key":"887_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159878","volume":"11","author":"SL Ashley","year":"2016","unstructured":"Ashley SL, Xia M, Murray S, O\u2019Dwyer DN, Grant E, White ES et al (2016) Six-SOMAmer index relating to immune, protease and angiogenic functions predicts progression in IPF. PLoS ONE 11:e0159878","journal-title":"PLoS ONE"},{"key":"887_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7080201","author":"SL Barratt","year":"2018","unstructured":"Barratt SL, Creamer A, Hayton C, Chaudhuri N (2018) Idiopathic pulmonary fibrosis (IPF): an overview. J Clin Med. https:\/\/doi.org\/10.3390\/jcm7080201","journal-title":"J Clin Med"},{"key":"887_CR15","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.7150\/ijms.113226","volume":"22","author":"J Liu","year":"2025","unstructured":"Liu J, Yi Z, Chen T, Ying Y, Hu Y (2025) An overview of the role of genetic factors in idiopathic pulmonary fibrosis: insights from epidemiology to prognosis. Int J Med Sci 22:2992\u20133006","journal-title":"Int J Med Sci"},{"issue":"Suppl 2","key":"887_CR16","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1513\/AnnalsATS.201503-110AW","volume":"12","author":"IV Yang","year":"2015","unstructured":"Yang IV, Fingerlin TE, Evans CM, Schwarz MI, Schwartz DA (2015) MUC5B and idiopathic pulmonary fibrosis. Ann Am Thorac Soc 12(Suppl 2):S193\u2013S199","journal-title":"Ann Am Thorac Soc"},{"key":"887_CR17","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","volume":"364","author":"MA Seibold","year":"2011","unstructured":"Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE et al (2011) A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364:1503\u20131512","journal-title":"N Engl J Med"},{"key":"887_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/CLEP.S54815","volume":"5","author":"B Ley","year":"2013","unstructured":"Ley B, Collard HR (2013) Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 5:483\u2013492","journal-title":"Clin Epidemiol"},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/thoraxjnl-2016-209172","volume":"71","author":"SK Mathai","year":"2016","unstructured":"Mathai SK, Newton CA, Schwartz DA, Garcia CK (2016) Pulmonary fibrosis in the era of stratified medicine. Thorax 71:1154\u20131160","journal-title":"Thorax"},{"key":"887_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","volume":"9","author":"PJ Wolters","year":"2014","unstructured":"Wolters PJ, Collard HR, Jones KD (2014) Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol Mech Dis 9:157\u2013179","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"887_CR21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1164\/rccm.201312-2221PP","volume":"189","author":"M Selman","year":"2014","unstructured":"Selman M, Pardo A (2014) Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med 189:1161\u20131172","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1183\/13993003.00398-2016","volume":"48","author":"M Selman","year":"2016","unstructured":"Selman M, L\u00f3pez-Ot\u00edn C, Pardo A (2016) Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J 48:538\u2013552","journal-title":"Eur Respir J"},{"key":"887_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/qjmed\/hcw117","volume":"109","author":"TM Maher","year":"2016","unstructured":"Maher TM (2016) Precision medicine in idiopathic pulmonary fibrosis. QJM 109:585\u2013587","journal-title":"QJM"},{"key":"887_CR24","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1164\/rccm.201810-1895ST","volume":"198","author":"AC Wu","year":"2018","unstructured":"Wu AC, Kiley JP, Noel PJ, Amur S, Burchard EG, Clancy JP et al (2018) Current status and future opportunities in lung precision medicine research with a focus on biomarkers. An American thoracic society\/national heart, lung, and blood institute research statement. Am J Respir Crit Care Med 198:e116\u2013e136","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1586\/17476348.2015.1062367","volume":"9","author":"I Campo","year":"2015","unstructured":"Campo I, Zorzetto M, Bonella F (2015) Facts and promises on lung biomarkers in interstitial lung diseases. Expert Rev Respir Med 9:437\u2013457","journal-title":"Expert Rev Respir Med"},{"key":"887_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622598","volume":"11","author":"A Watson","year":"2020","unstructured":"Watson A, Madsen J, Clark HW (2020) SP-A and SP-D: dual functioning immune molecules with antiviral and immunomodulatory properties. Front Immunol 11:622598","journal-title":"Front Immunol"},{"key":"887_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.virol.2021.11.006","volume":"566","author":"N Naderi","year":"2022","unstructured":"Naderi N, Rahimzadeh M (2022) Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: a systematic review and meta-analyses. Virology 566:106\u2013113","journal-title":"Virology"},{"key":"887_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13111607","author":"AS Zamfir","year":"2023","unstructured":"Zamfir AS, Zabara ML, Arcana RI, Cernomaz TA, Zabara-Antal A, Marcu MTD et al (2023) Exploring the role of biomarkers associated with alveolar damage and dysfunction in idiopathic pulmonary fibrosis-a systematic review. J Pers Med. https:\/\/doi.org\/10.3390\/jpm13111607","journal-title":"J Pers Med"},{"key":"887_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.606462","volume":"7","author":"A Venosa","year":"2020","unstructured":"Venosa A (2020) Senescence in pulmonary fibrosis: between aging and exposure. Front Med 7:606462","journal-title":"Front Med"},{"key":"887_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1165\/rcmb.2014-0246OC","volume":"54","author":"O Garcia","year":"2016","unstructured":"Garcia O, Hiatt MJ, Lundin A, Lee J, Reddy R, Navarro S et al (2016) Targeted type 2 alveolar cell depletion. A dynamic functional model for lung injury repair. Am J Respir Cell Mol Biol 54:319\u2013330","journal-title":"Am J Respir Cell Mol Biol"},{"key":"887_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173864","author":"S Majewski","year":"2021","unstructured":"Majewski S, Szewczyk K, \u017bal A, Bia\u0142as AJ, Mi\u0142kowska-Dymanowska J, Piotrowski WJ (2021) Serial measurements of circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and periostin in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy: an exploratory study. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10173864","journal-title":"J Clin Med"},{"key":"887_CR32","doi-asserted-by":"publisher","unstructured":"Ghonim MA, Boyd DF, Flerlage T, Thomas PG. Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside. J Clin Invest. 2023;133(17):e170499Ghonim MA, Boyd DF, Flerlage T, Thomas PG (2023) Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside. J Clin Invest 133 https:\/\/doi.org\/10.1172\/JCI170499","DOI":"10.1172\/JCI170499"},{"key":"887_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","volume":"44","author":"TA Wynn","year":"2016","unstructured":"Wynn TA, Vannella KM (2016) Macrophages in tissue repair, regeneration, and fibrosis. Immunity 44:450\u2013462","journal-title":"Immunity"},{"key":"887_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","volume":"173","author":"A Prasse","year":"2006","unstructured":"Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T et al (2006) A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173:781\u2013792","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR35","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3389\/fimmu.2017.01908","volume":"8","author":"C Xia","year":"2017","unstructured":"Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X (2017) S100 proteins as an important regulator of macrophage inflammation. Front Immunol 8:1908","journal-title":"Front Immunol"},{"issue":"17","key":"887_CR36","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/cells12172193","volume":"12","author":"D Pokhreal","year":"2023","unstructured":"Pokhreal D, Crestani B, Helou DG (2023) Macrophage implication in IPF: updates on immune, epigenetic, and metabolic pathways. Cells 12(17):2193","journal-title":"Cells"},{"key":"887_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.744","volume":"5","author":"J Wang","year":"2024","unstructured":"Wang J, Li K, Hao D, Li X, Zhu Y, Yu H et al (2024) Pulmonary fibrosis: pathogenesis and therapeutic strategies. MedComm 5:e744","journal-title":"MedComm"},{"key":"887_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23136894","author":"L Chuli\u00e1-Peris","year":"2022","unstructured":"Chuli\u00e1-Peris L, Carreres-Rey C, Gabasa M, Alcaraz J, Carretero J, Pereda J (2022) Matrix metalloproteinases and their inhibitors in pulmonary fibrosis: EMMPRIN\/CD147 comes into play. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23136894","journal-title":"Int J Mol Sci"},{"key":"887_CR39","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1164\/rccm.201510-2032PP","volume":"193","author":"K Izuhara","year":"2016","unstructured":"Izuhara K, Conway SJ, Moore BB, Matsumoto H, Holweg CT, Matthews JG et al (2016) Roles of periostin in respiratory disorders. Am J Respir Crit Care Med 193:949\u2013956","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-022-00856-w","volume":"12","author":"X Zhao","year":"2022","unstructured":"Zhao X, Chen J, Sun H, Zhang Y, Zou D (2022) New insights into fibrosis from the ECM degradation perspective: the macrophage-MMP-ECM interaction. Cell Biosci 12:117","journal-title":"Cell Biosci"},{"key":"887_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23543","volume":"10","author":"W Zhu","year":"2024","unstructured":"Zhu W, Liu C, Tan C, Zhang J (2024) Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis. Heliyon 10:e23543","journal-title":"Heliyon"},{"key":"887_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","volume":"50","author":"N Ishikawa","year":"2012","unstructured":"Ishikawa N, Hattori N, Yokoyama A, Kohno N (2012) Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 50:3\u201313","journal-title":"Respir Investig"},{"key":"887_CR43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00795-007-0382-7","volume":"40","author":"Y Ohtsuki","year":"2007","unstructured":"Ohtsuki Y, Fujita J, Hachisuka Y, Uomoto M, Okada Y, Yoshinouchi T et al (2007) Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and in interstitial pneumonia. Med Mol Morphol 40:198\u2013202","journal-title":"Med Mol Morphol"},{"key":"887_CR44","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1159\/000503689","volume":"98","author":"M Xue","year":"2019","unstructured":"Xue M, Guo Z, Cai C, Sun B, Wang H (2019) Evaluation of the diagnostic efficacies of serological markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia. Respiration 98:534\u2013545","journal-title":"Respiration"},{"key":"887_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10753-018-00955-2","volume":"42","author":"D Bennett","year":"2019","unstructured":"Bennett D, Salvini M, Fui A, Cillis G, Cameli P, Mazzei MA et al (2019) Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP. Inflammation 42:463\u2013470","journal-title":"Inflammation"},{"key":"887_CR46","first-page":"93","volume":"39","author":"C Zhu","year":"2016","unstructured":"Zhu C, Zhao YB, Kong LF, Li ZH, Kang J (2016) [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases]. Zhonghua Jie He He Hu Xi Za Zhi 39:93\u201397","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"887_CR47","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.21037\/jtd.2018.07.76","volume":"10","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Luo Q, Han Q, Huang J, Ou Y, Chen M et al (2018) Sequential changes of serum KL-6 predict the progression of interstitial lung disease. J Thorac Dis 10:4705\u20134714","journal-title":"J Thorac Dis"},{"key":"887_CR48","doi-asserted-by":"publisher","first-page":"8564","DOI":"10.1038\/s41598-022-12399-8","volume":"12","author":"C Chung","year":"2022","unstructured":"Chung C, Kim J, Cho HS, Kim HC (2022) Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis. Sci Rep 12:8564","journal-title":"Sci Rep"},{"key":"887_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.resinv.2016.09.003","volume":"55","author":"K Wakamatsu","year":"2017","unstructured":"Wakamatsu K, Nagata N, Kumazoe H, Oda K, Ishimoto H, Yoshimi M et al (2017) Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig 55:16\u201323","journal-title":"Respir Investig"},{"key":"887_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2024.102516","volume":"90","author":"M d'Alessandro","year":"2024","unstructured":"d\u2019Alessandro M, Conticini E, Bergantini L, Mazzei MA, Bellisai F, Selvi E et al (2024) Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease. Tissue Cell 90:102516","journal-title":"Tissue Cell"},{"key":"887_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031173","author":"LB Jehn","year":"2023","unstructured":"Jehn LB, Costabel U, Boerner E, W\u00e4lscher J, Theegarten D, Taube C et al (2023) Serum KL-6 as a biomarker of progression at any time in fibrotic interstitial lung disease. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12031173","journal-title":"J Clin Med"},{"key":"887_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244114","volume":"15","author":"UW Ko","year":"2020","unstructured":"Ko UW, Cho EJ, Oh HB, Koo HJ, Do KH, Song JW (2020) Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease. PLoS ONE 15:e0244114","journal-title":"PLoS ONE"},{"key":"887_CR53","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12931-022-02273-6","volume":"23","author":"MG Choi","year":"2022","unstructured":"Choi MG, Choi SM, Lee JH, Kim JY, Song JW (2022) Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis. Respir Res 23:334","journal-title":"Respir Res"},{"key":"887_CR54","volume":"41","author":"G Sanjan","year":"2024","unstructured":"Sanjan G, Sharma P, Banerjee S, Sivaramakrishnan P, Sherwani P, Atif Mirza A et al (2024) Correlation of serum Krebs von den Lungen-6 levels with fibrosis score on high resolution chest tomography and pulmonary function parameters in treatment na\u00efve idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 41:e2024044","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"887_CR55","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.arbres.2019.08.020","volume":"56","author":"L Guo","year":"2020","unstructured":"Guo L, Yang Y, Liu F, Jiang C, Yang Y, Pu H et al (2020) Clinical research on prognostic evaluation of subjects with IPF by peripheral blood biomarkers, quantitative imaging characteristics and pulmonary function parameters. Arch Bronconeumol 56:365\u2013372","journal-title":"Arch Bronconeumol"},{"key":"887_CR56","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1111\/crj.12946","volume":"12","author":"H Ishii","year":"2018","unstructured":"Ishii H, Kushima H, Kinoshita Y, Fujita M, Watanabe K (2018) The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression. Clin Respir J 12:2411\u20132418","journal-title":"Clin Respir J"},{"key":"887_CR57","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1515\/cclm-2021-0199","volume":"59","author":"E Aloisio","year":"2021","unstructured":"Aloisio E, Braga F, Puricelli C, Panteghini M (2021) Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Chem Lab Med 59:1400\u20131408","journal-title":"Clin Chem Lab Med"},{"key":"887_CR58","doi-asserted-by":"publisher","first-page":"6729","DOI":"10.2147\/JIR.S458428","volume":"17","author":"M Liu","year":"2024","unstructured":"Liu M, Cheng ZJ, Chen J, Li H, Xue M, Fu X et al (2024) A pilot HRCT follow-up study to test the feasibility of predictive efficacy of serum periostin in idiopathic pulmonary fibrosis. J Inflamm Res 17:6729\u20136742","journal-title":"J Inflamm Res"},{"key":"887_CR59","doi-asserted-by":"publisher","DOI":"10.1177\/1753466620963015","volume":"14","author":"H Feng","year":"2020","unstructured":"Feng H, Zhao Y, Li Z, Kang J (2020) Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Ther Adv Respir Dis 14:1753466620963015","journal-title":"Ther Adv Respir Dis"},{"key":"887_CR60","doi-asserted-by":"publisher","first-page":"L950","DOI":"10.1152\/ajplung.2000.279.5.L950","volume":"279","author":"L V\u00e1zquez de Lara","year":"2000","unstructured":"V\u00e1zquez de Lara L, Becerril C, Monta\u00f1o M, Ramos C, Maldonado V, Mel\u00e9ndez J et al (2000) Surfactant components modulate fibroblast apoptosis and type I collagen and collagenase-1 expression. Am J Physiol Lung Cell Mol Physiol 279:L950\u2013L957","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"887_CR61","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1164\/rccm.201103-0561OC","volume":"185","author":"Y Aono","year":"2012","unstructured":"Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, Sone S et al (2012) Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 185:525\u2013536","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR62","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1378\/chest.08-2209","volume":"135","author":"BW Kinder","year":"2009","unstructured":"Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI et al (2009) Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 135:1557\u20131563","journal-title":"Chest"},{"key":"887_CR63","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12931-020-01582-y","volume":"21","author":"K Ikeda","year":"2020","unstructured":"Ikeda K, Chiba H, Nishikiori H, Azuma A, Kondoh Y, Ogura T et al (2020) Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respir Res 21:316","journal-title":"Respir Res"},{"key":"887_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13091307","author":"K Domvri","year":"2023","unstructured":"Domvri K, Organtzis I, Apostolopoulos A, Fouka E, Kontakiotis T, Papakosta D (2023) Prognostic value of serum biomarkers in patients with Idiopathic Pulmonary Fibrosis in relation to disease progression. J Pers Med. https:\/\/doi.org\/10.3390\/jpm13091307","journal-title":"J Pers Med"},{"key":"887_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03224-1","volume":"24","author":"K Wakamatsu","year":"2024","unstructured":"Wakamatsu K, Nagata N, Kumazoe H, Hara M, Asai S, Noda N et al (2024) Prognostic performance of Krebs von den Lungen-6, surfactant protein A, surfactant protein D levels in the serum and bronchoalveolar lavage fluid in chronic fibrosing interstitial pneumonia: a retrospective study. BMC Pulm Med 24:404","journal-title":"BMC Pulm Med"},{"key":"887_CR66","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.chest.2018.08.1083","volume":"154","author":"G Raghu","year":"2018","unstructured":"Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux ML et al (2018) Idiopathic Pulmonary Fibrosis: prospective, case-controlled study of natural history and circulating biomarkers. Chest 154:1359\u20131370","journal-title":"Chest"},{"key":"887_CR67","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00335-2023","author":"TM Maher","year":"2024","unstructured":"Maher TM, Jenkins RG, Cottin V, Nishioka Y, Noth I, Selman M et al (2024) Circulating biomarkers and progression of Idiopathic Pulmonary Fibrosis: data from the INMARK trial. ERJ Open Res. https:\/\/doi.org\/10.1183\/23120541.00335-2023","journal-title":"ERJ Open Res"},{"key":"887_CR68","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12890-019-1032-2","volume":"19","author":"T Hanaka","year":"2019","unstructured":"Hanaka T, Kido T, Noguchi S, Yamada S, Noguchi H, Guo X et al (2019) The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis. BMC Pulm Med 19:265","journal-title":"BMC Pulm Med"},{"key":"887_CR69","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4240\/wjgs.v12.i12.468","volume":"12","author":"T Lee","year":"2020","unstructured":"Lee T, Teng TZJ, Shelat VG (2020) Carbohydrate antigen 19\u20139 - tumor marker: past, present, and future. World J Gastrointest Surg 12:468\u2013490","journal-title":"World J Gastrointest Surg"},{"key":"887_CR70","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1378\/chest.114.6.1542","volume":"114","author":"YC Lee","year":"1998","unstructured":"Lee YC, Chern JH, Lai SL, Perng RP (1998) Sialyl stage-specific embryonic antigen-1: a useful marker for differentiating the etiology of pleural effusion. Chest 114:1542\u20131545","journal-title":"Chest"},{"key":"887_CR71","doi-asserted-by":"publisher","first-page":"7383","DOI":"10.21037\/jtd-24-922","volume":"16","author":"Y Wang","year":"2024","unstructured":"Wang Y, Sun D, Song Y, Du X, Wu N, Ye Q (2024) Assessment of tumor biomarkers for prognosis in interstitial lung disease associated with connective tissue disease: a prospective study. J Thorac Dis 16:7383\u20137396","journal-title":"J Thorac Dis"},{"key":"887_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20683-w","volume":"12","author":"BS Kwon","year":"2022","unstructured":"Kwon BS, Kim ES, Lim SY, Song MJ, Kim YW, Kim HJ et al (2022) The significance of elevated tumor markers among patients with interstitial lung diseases. Sci Rep 12:16702","journal-title":"Sci Rep"},{"key":"887_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-021-01688-4","volume":"16","author":"Q Chen","year":"2021","unstructured":"Chen Q, Lu Q, Fei X, Li C, Li B (2021) Elevated tumor markers in a benign lung disease. J Cardiothorac Surg 16:308","journal-title":"J Cardiothorac Surg"},{"key":"887_CR74","first-page":"887","volume":"27","author":"Y Shiota","year":"1989","unstructured":"Shiota Y, Furuya K, Kitade M, Ueda N (1989) [CEA and CA19-9 in BALF from patients with idiopathic interstitial pneumonia]. Nihon Kyobu Shikkan Gakkai Zasshi 27:887\u2013893","journal-title":"Nihon Kyobu Shikkan Gakkai Zasshi"},{"key":"887_CR75","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02913488","volume":"50","author":"K Okabayashi","year":"2002","unstructured":"Okabayashi K, Motohiro A, Ueda H, Ondo K, Kawahara K, Shirakusa T (2002) Subcarinal bronchogenic cyst with high carbohydrate antigen 19\u20139 production. Jpn J Thorac Cardiovasc Surg 50:46\u201348","journal-title":"Jpn J Thorac Cardiovasc Surg"},{"key":"887_CR76","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/thx.50.6.651","volume":"50","author":"A Ohwada","year":"1995","unstructured":"Ohwada A, Takahashi H, Nagaoka I, Iwabuchi K, Mikami O, Kira S (1995) Effect of cigarette smoke on the mRNA and protein expression of carcinoembryonic antigen (CEA), a possible chemoattractant for neutrophils in human bronchioloalveolar tissues. Thorax 50:651\u2013657","journal-title":"Thorax"},{"key":"887_CR77","doi-asserted-by":"publisher","DOI":"10.1177\/1479973120958428","volume":"17","author":"E Balestro","year":"2020","unstructured":"Balestro E, Castelli G, Bernardinello N, Cocconcelli E, Biondini D, Fracasso F et al (2020) CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): correlation with functional decline. Chron Respir Dis 17:1479973120958428","journal-title":"Chron Respir Dis"},{"key":"887_CR78","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1183\/09031936.00146510","volume":"38","author":"S L\u00f6ffek","year":"2011","unstructured":"L\u00f6ffek S, Schilling O, Franzke CW (2011) Series \u201cmatrix metalloproteinases in lung health and disease\u201d: biological role of matrix metalloproteinases: a critical balance. Eur Respir J 38:191\u2013208","journal-title":"Eur Respir J"},{"key":"887_CR79","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.pccm.2023.05.002","volume":"1","author":"S Almuntashiri","year":"2023","unstructured":"Almuntashiri S, Alhumaid A, Zhu Y, Han Y, Dutta S, Khilji O et al (2023) TIMP-1 and its potential diagnostic and prognostic value in pulmonary diseases. Chin Med J Pulm Crit Care Med 1:67\u201376","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"887_CR80","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00191-2022","author":"J Jaffar","year":"2022","unstructured":"Jaffar J, Wong M, Fishbein GA, Alhamdoosh M, McMillan L, Gamell-Fulla C et al (2022) Matrix metalloproteinase-7 is increased in lung bases but not apices in idiopathic pulmonary fibrosis. ERJ Open Res. https:\/\/doi.org\/10.1183\/23120541.00191-2022","journal-title":"ERJ Open Res"},{"key":"887_CR81","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.oto.2009.10.003","volume":"20","author":"X Mu","year":"2010","unstructured":"Mu X, Bellayr I, Walters T, Li Y (2010) Mediators leading to fibrosis\u2014how to measure and control them in tissue engineering. Oper Tech Orthop 20:110\u2013118","journal-title":"Oper Tech Orthop"},{"key":"887_CR82","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1378\/chest.11-2735","volume":"143","author":"JW Song","year":"2013","unstructured":"Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS (2013) Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 143:1422\u20131429","journal-title":"Chest"},{"key":"887_CR83","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1164\/rccm.201101-0058OC","volume":"185","author":"TJ Richards","year":"2012","unstructured":"Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D et al (2012) Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 185:67\u201376","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR84","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/resp.12920","volume":"22","author":"A Tzouvelekis","year":"2017","unstructured":"Tzouvelekis A, Herazo-Maya JD, Slade M, Chu JH, Deiuliis G, Ryu C et al (2017) Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology 22:486\u2013493","journal-title":"Respirology"},{"key":"887_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-015-0280-9","volume":"16","author":"A Sokai","year":"2015","unstructured":"Sokai A, Handa T, Tanizawa K, Oga T, Uno K, Tsuruyama T et al (2015) Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir Res 16:120","journal-title":"Respir Res"},{"key":"887_CR86","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01612-2021","author":"FA Khan","year":"2022","unstructured":"Khan FA, Stewart I, Saini G, Robinson KA, Jenkins RG (2022) A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01612-2021","journal-title":"Eur Respir J"},{"key":"887_CR87","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1164\/rccm.201505-0862OC","volume":"194","author":"ES White","year":"2016","unstructured":"White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR et al (2016) Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med 194:1242\u20131251","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR88","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12890-020-1103-4","volume":"20","author":"JL Todd","year":"2020","unstructured":"Todd JL, Vinisko R, Liu Y, Neely ML, Overton R, Flaherty KR et al (2020) Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO registry cohort. BMC Pulm Med 20:64","journal-title":"BMC Pulm Med"},{"key":"887_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050093","volume":"5","author":"IO Rosas","year":"2008","unstructured":"Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE et al (2008) MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 5:e93","journal-title":"PLoS Med"},{"key":"887_CR90","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pccm.2024.04.003","volume":"2","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Peng F, Zhou Y (2024) Biomarkers in idiopathic pulmonary fibrosis: current insight and future direction. Chin Med J Pulmonary Critic Care Med 2:72\u201379Zheng Z, Peng F, Zhou Y (2024) Biomarkers in idiopathic pulmonary fibrosis: current insight and future direction. Chin Med J Pulmonary Critic Care Med 2:72\u201379","journal-title":"Chin Med J Pulmonary Critic Care Med"},{"key":"887_CR91","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","volume":"3","author":"RG Jenkins","year":"2015","unstructured":"Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R et al (2015) Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 3:462\u2013472","journal-title":"Lancet Respir Med"},{"key":"887_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104591","volume":"152","author":"S Mahalanobish","year":"2020","unstructured":"Mahalanobish S, Saha S, Dutta S, Sil PC (2020) Matrix metalloproteinase: an upcoming therapeutic approach for idiopathic pulmonary fibrosis. Pharmacol Res 152:104591","journal-title":"Pharmacol Res"},{"key":"887_CR93","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1183\/09031936.00059810","volume":"37","author":"M Okamoto","year":"2011","unstructured":"Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K et al (2011) Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 37:1119\u20131127","journal-title":"Eur Respir J"},{"key":"887_CR94","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1165\/rcmb.2011-0115OC","volume":"46","author":"M Uchida","year":"2012","unstructured":"Uchida M, Shiraishi H, Ohta S, Arima K, Taniguchi K, Suzuki S et al (2012) Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol 46:677\u2013686","journal-title":"Am J Respir Cell Mol Biol"},{"key":"887_CR95","doi-asserted-by":"publisher","first-page":"L1046","DOI":"10.1152\/ajplung.00139.2012","volume":"303","author":"PK Naik","year":"2012","unstructured":"Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA et al (2012) Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 303:L1046\u2013L1056","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"887_CR96","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/mi.2016.61","volume":"10","author":"SL Ashley","year":"2017","unstructured":"Ashley SL, Wilke CA, Kim KK, Moore BB (2017) Periostin regulates fibrocyte function to promote myofibroblast differentiation and lung fibrosis. Mucosal Immunol 10:341\u2013351","journal-title":"Mucosal Immunol"},{"key":"887_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55040083","author":"F Salton","year":"2019","unstructured":"Salton F, Volpe MC, Confalonieri M (2019) Epithelial-mesenchymal transition in the pathogenesis of idiopathic pulmonary fibrosis. Medicina. https:\/\/doi.org\/10.3390\/medicina55040083","journal-title":"Medicina"},{"key":"887_CR98","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1007\/s00018-017-2649-z","volume":"74","author":"DN O'Dwyer","year":"2017","unstructured":"O\u2019Dwyer DN, Moore BB (2017) The role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci 74:4305\u20134314","journal-title":"Cell Mol Life Sci"},{"key":"887_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174547","volume":"12","author":"S Ohta","year":"2017","unstructured":"Ohta S, Okamoto M, Fujimoto K, Sakamoto N, Takahashi K, Yamamoto H et al (2017) The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS ONE 12:e0174547","journal-title":"PLoS ONE"},{"key":"887_CR100","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/CIRCRESAHA.120.316943","volume":"127","author":"X Nie","year":"2020","unstructured":"Nie X, Shen C, Tan J, Wu Z, Wang W, Chen Y et al (2020) Periostin: A potential therapeutic target for pulmonary hypertension? Circ Res 127:1138\u20131152","journal-title":"Circ Res"},{"key":"887_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19768354.2023.2300437","volume":"28","author":"D Lee","year":"2024","unstructured":"Lee D, Lee H, Jo HN, Yun E, Kwon BS, Kim J et al (2024) Endothelial periostin regulates vascular remodeling by promoting endothelial dysfunction in pulmonary arterial hypertension. Anim Cells Syst 28:1\u201314","journal-title":"Anim Cells Syst"},{"key":"887_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105945","volume":"171","author":"JU Lee","year":"2020","unstructured":"Lee JU, Chang HS, Shim EY, Park JS, Koh ES, Shin HK et al (2020) The S100 calcium-binding protein A4 level is elevated in the lungs of patients with idiopathic pulmonary fibrosis. Respir Med 171:105945","journal-title":"Respir Med"},{"key":"887_CR103","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1172\/JCI90832","volume":"127","author":"H Xia","year":"2017","unstructured":"Xia H, Gilbertsen A, Herrera J, Racila E, Smith K, Peterson M et al (2017) Calcium-binding protein S100A4 confers mesenchymal progenitor cell fibrogenicity in idiopathic pulmonary fibrosis. J Clin Invest 127:2586\u20132597","journal-title":"J Clin Invest"},{"key":"887_CR104","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/resp.13707","volume":"25","author":"N Akiyama","year":"2020","unstructured":"Akiyama N, Hozumi H, Isayama T, Okada J, Sugiura K, Yasui H et al (2020) Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis. Respirology 25:743\u2013749","journal-title":"Respirology"},{"key":"887_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01776","volume":"9","author":"Y Li","year":"2018","unstructured":"Li Y, Bao J, Bian Y, Erben U, Wang P, Song K et al (2018) S100A4(+) macrophages are necessary for pulmonary fibrosis by activating lung fibroblasts. Front Immunol 9:1776","journal-title":"Front Immunol"},{"key":"887_CR106","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e13","volume":"39","author":"JU Lee","year":"2024","unstructured":"Lee JU, Kim MK, Kim MS, Lee SJ, Park SL, Chang HS et al (2024) S100 calcium-binding protein A9, a potential novel diagnostic biomarker for idiopathic pulmonary fibrosis. J Korean Med Sci 39:e13","journal-title":"J Korean Med Sci"},{"key":"887_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.810338","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, He Y, Chen S, Wang Q, Yang Y, Shen D et al (2022) S100A12 as biomarker of disease severity and prognosis in patients with idiopathic pulmonary fibrosis. Front Immunol 13:810338","journal-title":"Front Immunol"},{"key":"887_CR108","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1165\/rcmb.2006-0033OC","volume":"35","author":"IG Luzina","year":"2006","unstructured":"Luzina IG, Highsmith K, Pochetuhen K, Nacu N, Rao JN, Atamas SP (2006) PKCalpha mediates CCL18-stimulated collagen production in pulmonary fibroblasts. Am J Respir Cell Mol Biol 35:298\u2013305","journal-title":"Am J Respir Cell Mol Biol"},{"key":"887_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13101715","author":"E Zanatta","year":"2023","unstructured":"Zanatta E, Martini A, Depascale R, Gamba A, Tonello M, Gatto M et al (2023) CCL18 as a biomarker of interstitial lung disease (ILD) and progressive fibrosing ILD in patients with idiopathic inflammatory myopathies. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics13101715","journal-title":"Diagnostics"},{"key":"887_CR110","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1164\/rccm.200808-1201OC","volume":"179","author":"A Prasse","year":"2009","unstructured":"Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR et al (2009) Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179:717\u2013723","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR111","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1080\/08923973.2016.1247852","volume":"38","author":"Y Saito","year":"2016","unstructured":"Saito Y, Azuma A, Matsuda K, Kamio K, Abe S, Gemma A (2016) Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation. Immunopharmacol Immunotoxicol 38:464\u2013471","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"887_CR112","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1164\/rccm.202301-0117OC","volume":"209","author":"JM Oldham","year":"2024","unstructured":"Oldham JM, Huang Y, Bose S, Ma SF, Kim JS, Schwab A et al (2024) Proteomic biomarkers of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 209:1111\u20131120","journal-title":"Am J Respir Crit Care Med"},{"key":"887_CR113","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.rmed.2017.08.021","volume":"131","author":"K Ikeda","year":"2017","unstructured":"Ikeda K, Shiratori M, Chiba H, Nishikiori H, Yokoo K, Saito A et al (2017) Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Med 131:184\u2013191","journal-title":"Respir Med"},{"key":"887_CR114","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/rej.2020.2401","volume":"24","author":"GE Carpagnano","year":"2021","unstructured":"Carpagnano GE, Soccio P, Scioscia G, Palladino GP, Foschino Barbaro MP, Lacedonia D (2021) The potential role of airways periostin in the clinical practice of patients affected by idiopathic pulmonary fibrosis. Rejuvenation Res 24:302\u2013306","journal-title":"Rejuvenation Res"},{"key":"887_CR115","volume":"41","author":"A Kay\u0131k\u00e7\u0131","year":"2024","unstructured":"Kay\u0131k\u00e7\u0131 A, Alatas F, Alatas IO, Y\u0131ld\u0131r\u0131m H, Ozen H (2024) The role of biomarkers in the diagnosis and treatment follow-up of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 41:e2024015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00887-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00887-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00887-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:02:22Z","timestamp":1777309342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-026-00887-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00887-x","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of Interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable. This article is a narrative review of previously published literature and does not involve any studies with human participants or animals performed by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}],"article-number":"21"}}